Bristol Myers Squibb disclosed a previously unreported fatal event in its multiple sclerosis CAR T trial of zola-cel (zolacabtagene autoleucel), describing the death as septic pneumonia following infusion and high-dose cyclophosphamide. The disclosure comes after BMS reported that its own trial was halted earlier this year in response to competitor trial deaths, but BMS said the death occurred after the data cutoff point.